MeSH Browser

MeSH Heading: 11-beta-Hydroxysteroid Dehydrogenase Type 2
Tree Number(s): D08.811.682.047.436.174.600; D08.811.682.047.820.100.600
Unique ID: D043209
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D043209
Scope Note: An high-affinity, NAD-dependent 11-beta-hydroxysteroid dehydrogenase that acts unidirectionally to catalyze the dehydrogenation of CORTISOL to CORTISONE. It is found predominantly in mineralocorticoid target tissues such as the KIDNEY; COLON; SWEAT GLANDS; and the PLACENTA. Absence of the enzyme leads to a fatal form of childhood hypertension termed, APPARENT MINERALOCORTICOID EXCESS SYNDROME.
Entry Term(s): 11 beta-HSD2; 11 beta-Hydroxysteroid Dehydrogenase Type 2; 11beta-HSD2; 11beta-HSD2 Reductase; 11beta-Hydroxysteroid Dehydrogenase Type 2
Previous Indexing: Hydroxysteroid Dehydrogenases (1992-2003)
Public MeSH Note: 2004; 11 BETA-HSD2 was indexed under HYDROXYSTEROID DEHYDROGENASES 1992-2003
History Note: 2004; for 11 BETA-HSD2 use 11 BETA-HYDROXYSTEROID DEHYDROGENASES (NM) 1992-2003
Entry Combination: deficiency:Mineralocorticoid Excess Syndrome, Apparent
Date Established: 2004/01/01
Date of Entry: 2003/07/09
Revision Date: 2013/07/08

Entry Combination: deficiency:Mineralocorticoid Excess Syndrome, Apparent
Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

analysis (AN)

antagonists & inhibitors (AI)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

drug effects (DE)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

ultrastructure (UL)

urine (UR)

Concept UI: M0076299
Scope Note: An high-affinity, NAD-dependent 11-beta-hydroxysteroid dehydrogenase that acts unidirectionally to catalyze the dehydrogenation of CORTISOL to CORTISONE. It is found predominantly in mineralocorticoid target tissues such as the KIDNEY; COLON; SWEAT GLANDS; and the PLACENTA. Absence of the enzyme leads to a fatal form of childhood hypertension termed, APPARENT MINERALOCORTICOID EXCESS SYNDROME.
Terms: 11-beta-Hydroxysteroid Dehydrogenase Type 2 Preferred Term
Term UI T526968
Date11/25/2002
LexicalTag NON
ThesaurusID NLM (2004); 11 beta-HSD2
Term UI T106302
Date01/01/1955
LexicalTag ACR
ThesaurusID NLM (2004); 11 beta-Hydroxysteroid Dehydrogenase Type 2
Term UI T405109
Date01/14/2000
LexicalTag NON
ThesaurusID NLM (2004); 11beta-HSD2
Term UI T405110
Date01/14/2000
LexicalTag ACR
ThesaurusID NLM (2004); 11beta-HSD2 Reductase
Term UI T526969
Date11/25/2002
LexicalTag ABB
ThesaurusID NLM (2004); 11beta-Hydroxysteroid Dehydrogenase Type 2
Term UI T542236
Date06/02/2003
LexicalTag NON
ThesaurusID NLM (2004)

11-beta-Hydroxysteroid Dehydrogenase Type 2 MeSH Descriptor Data 2024